Table 2.

Uni- and multivariate survival analyses for Group 3 MB cohort

Variables Group 3	HR U PFS	p-value	HR M PFS	p-value	HR U OS	p-value	HR M OS	p-value
M stage: M2-3 vs. M0-1	13.26	< 0.01	2.71	0.04	19.65	< 0.01	3.28	< 0.01
Histology: LCA vs. Classic	11.58	< 0.01	–	–	14.51	< 0.01	–	–
CHT alone vs. RT + CHT	44.91	< 0.01	4.31	< 0.01	39.31	< 0.01	3.25	< 0.01
Amplifications: yes vs. no	22.95	< 0.01	–	–	22.79	< 0.01	–	–
MYC amplification: yes vs. no	49.32	< 0.01	3.83	< 0.01	64.61	< 0.01	4.34	< 0.01
Trisomy 7: yes vs. no	0.47	0.04	–	–	0.38	< 0.01	–	–
Monosomy 8: yes vs. no	0.35	< 0.01	–	–	0.46	0.03	–	–
i(17q): yes vs. no	11.87	< 0.01	–	–	14.67	< 0.01	–	–
18q gain: yes vs. no	0.38	< 0.01	–	–	0.37	< 0.01	–	–
Subgroup: II/III/V vs. IV/VII	5.36	0.02	–	–	7.91	< 0.01	–	–
MYC expression: high vs. low	53.14	< 0.01	–	–	67.41	< 0.01	–	–
KIRREL2 expression: high vs. low	73.41	< 0.01	7.38	< 0.01	78.71	< 0.01	8.87	< 0.01
ITPRL1 expression: high vs. low	40.51	< 0.01	–	–	47.45	< 0.01	–	–
DCAF4 expression: high vs. low	30.69	< 0.01	–	–	40.95	< 0.01	–	–
CTD1 expression: high vs. low	37.74	< 0.01	–	–	57.58	< 0.01	–	–
NPW expression: high vs. low	40.21	< 0.01	–	–	58.61	< 0.01	–	–

LCA large-cell anaplastic, CHT chemotherapy, RT radiotherapy, HR U hazard ration univariate analysis, HR M hazard ration multivariate model, PFS progression-free survival, OS overall survival, p-value log-rank test